A Feasibility Trial of Eye Movement Desensitization and Reprocessing Therapy- Integrative Treatment Group Protocol for Ongoing Traumatic Stress In Road Traffic Accident Survivors for Reduction of Post-traumatic Stress Symptoms

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorUniversity of the Punjab

About this trial

Road traffic accidents (RTAs) are a significant public health concern globally, accounting for a substantial proportion of morbidity and mortality. This study evaluates the feasibility and acceptability of the Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol for Ongoing Traumatic Stress (EMDR-IGTP-OTS) in the reduction of posttraumatic stress symptoms, depression, and anxiety, while improving the quality of life in individuals who have experienced traffic accidents. Using a randomized control design, participants aged 18-45 will be assessed at three-time points: pre-treatment, post-treatment, and one-month follow-up. The study employs the DASS-21, UIES-R, and WHOQOL-BREF as evaluation measures. Findings aim to expand evidence on trauma-focused interventions and explore their applicability in culturally diverse, resource-constrained settings.

Eligibility criteria

Qualifiers

Aged between 18 and 45 years.

Experienced a traffic accident 3 months to 10 years prior

Willing to participate and able to understand the intervention components.

Disqualifiers

Diagnosed with conditions such as schizophrenia or bipolar disorder, which require specialized treatment beyond the scope of this study.

History of severe head injuries resulting in neurological or cognitive deficits.

Participants who have experienced a traffic accident less than 3 months ago, as immediate post-traumatic responses may not have stabilized

Trial design

Treatments tested in this trial

  • Eye movement desensitization and reprocessing therapy integrative group treatment protocol for Ongoing traumatic stress

Treatment groups

35 Participants
are divided into 2 treatment groups

Sponsors and collaborators